The landing procedure for the new chronic kidney disease drug 'Kerendia' is in full swing in general hospitals in Korea ahead of its reimbursement listing.

According to industry sources, Bayer Korea's Kerendia (finerenone) recently passed the drug committee (DC) review at Sinchon Severance Hospital. It is also undergoing a landing process at major hospitals nationwide.

Kerendia, a treatment for chronic kidney disease associated with type 2 diabetes, will be listed for reimbursement next month (February).

With Chong Kun Dang joining as a domestic sales partner, full-scale promotional activities are expected to unfold along with the rapid landing process.

Ker